Cystic fibrosis-related diabetes (CFRD) is a distinct and increasingly prevalent complication of cystic fibrosis (CF). Unlike type 1 or type 2 diabetes, CFRD arises from the progressive destruction of the pancreas by thick, sticky mucus—a hallmark of CF. This damage targets the insulin-producing beta cells in the islets of Langerhans, leading to a relative insulin deficiency. The condition affects approximately 20% of adolescents and up to 50% of adults with CF, and its onset is often subtle, delaying diagnosis for years. Yet CFRD has a profound impact: it accelerates the decline in lung function, worsens nutritional status, and increases mortality. Managing CFRD is complex because it requires balancing intensive insulin therapy with the high-calorie, high-fat diet essential for CF patients to maintain weight and fight chronic infections. Understanding the hormonal shifts that drive CFRD is critical for developing effective, individualized treatment plans.

The Hormonal Ecosystem in Cystic Fibrosis

Hormones act as chemical messengers that regulate virtually every physiological process, including glucose metabolism. In cystic fibrosis, the CFTR gene mutation disrupts not only the exocrine pancreas but also endocrine cells throughout the body. Chronic inflammation, recurrent infections, and the metabolic demands of CF create a state of constant stress that further alters hormone secretion and action. This hormonal dysregulation is not a side effect—it is a core driver of CFRD. Unlike standard diabetes, where the primary defect is either insulin deficiency or insulin resistance, CFRD involves a complex interplay of multiple hormonal axes. Each axis must be understood to tailor therapy effectively.

Insulin: The Central Player in CFRD

Insulin is the primary hormone that lowers blood glucose by promoting cellular uptake, storage as glycogen, and inhibiting glucose production by the liver. In CF, pancreatic fibrosis progressively reduces beta-cell mass, leading to a decline in first-phase insulin secretion—the rapid spike of insulin that normally occurs after a meal. This blunted response causes postprandial hyperglycemia. Over time, total insulin output also falls, resulting in fasting hyperglycemia. The severity of insulin deficiency closely correlates with the degree of pancreatic exocrine insufficiency, which affects 85–90% of CF patients. Beyond glucose control, insulin has potent anabolic effects on muscle and fat tissue. CF patients often struggle with cachexia and low muscle mass, and the loss of insulin’s anabolic action directly contributes to declining lung function and overall health. Early recognition of insulin deficiency is key—delayed treatment accelerates the downward spiral.

Glucagon: The Overactive Counter-Regulator

Glucagon is secreted by pancreatic alpha cells and raises blood glucose by stimulating glycogen breakdown and glucose production in the liver. In healthy individuals, the insulin-to-glucagon ratio is tightly regulated. In CF, alpha cells are also damaged but less severely than beta cells. This creates an imbalance: relative glucagon excess compared to insulin. During fasting, inappropriate glucagon secretion can lead to paradoxical hyperglycemia. During acute illness or stress, glucagon spikes further worsen glucose control. Moreover, the normal suppression of glucagon after a carbohydrate-rich meal is impaired in CF, compounding postprandial hyperglycemia independent of insulin deficiency. Targeting glucagon dysregulation is an emerging avenue for CFRD therapy.

Cortisol and the Stress Response

Cortisol, a glucocorticoid released by the adrenal cortex during stress, has powerful hyperglycemic effects. It stimulates gluconeogenesis, reduces glucose uptake in peripheral tissues, and promotes protein breakdown. CF patients frequently experience physiologic stress from pulmonary exacerbations, hypoxia, systemic inflammation, and acute infections. This drives chronic cortisol elevation, which worsens insulin resistance and blood glucose control. Many CF patients also require systemic or inhaled corticosteroids for asthma, allergic bronchopulmonary aspergillosis (ABPA), or post-transplant immunosuppression. Steroid-induced hyperglycemia is a major challenge in CFRD management. During steroid bursts, proactive insulin dose adjustments and close monitoring are essential to prevent severe hyperglycemia.

Growth Hormone and IGF-1: Anabolic Imbalance

Growth hormone (GH) is known to cause insulin resistance by impairing insulin signaling in muscle and fat cells. In CF, GH secretion is often normal or even increased, but levels of insulin-like growth factor 1 (IGF-1)—the main effector of GH action—are low due to malnutrition and liver dysfunction. This creates a paradoxical state: GH continues to promote insulin resistance without the beneficial anabolic effects of IGF-1. Some CF patients are treated with recombinant GH for short stature or to improve lean body mass, which can further worsen glucose tolerance. Conversely, optimizing nutritional status to raise IGF-1 levels may improve insulin sensitivity and restore a more normal GH axis. The interplay between GH, IGF-1, and insulin is a delicate balance that requires careful monitoring during growth-promoting therapies.

Adipokines: Leptin and Adiponectin

Adipose tissue is an active endocrine organ that secretes adipokines—hormones that regulate energy balance and insulin sensitivity. Leptin signals satiety and energy expenditure; in CF, leptin levels are often elevated despite low body fat, likely due to chronic inflammation and leptin resistance. High leptin is associated with insulin resistance. Adiponectin, which enhances insulin sensitivity and has anti-inflammatory properties, is typically low in CF patients. Low adiponectin is linked to worse glucose tolerance and increased cardiovascular risk. The altered adipokine profile contributes to the metabolic disturbances seen in CFRD and may offer therapeutic targets in the future.

Sex Hormones: Estrogen, Progesterone, and Testosterone

Puberty is a critical period for the onset of CFRD. The dramatic changes in sex hormones during adolescence alter insulin sensitivity profoundly. Estrogen and progesterone can increase insulin resistance, while testosterone has more nuanced effects. Girls with CF often experience delayed puberty and low estrogen levels, but when estrogen rises, the risk of CFRD increases. Estrogen also affects immune function and lung inflammation, creating a bidirectional relationship between CFRD and pulmonary health. In males with CF, low testosterone due to CF-related hypogonadism is common, further impairing muscle mass and insulin sensitivity. Pregnancy in CF adds another layer of hormonal complexity—pregnancy-induced insulin resistance can unmask latent CFRD or worsen existing diabetes, requiring intensive insulin management to protect both mother and fetus.

Incretins: GLP-1 and GIP

Incretins are gut hormones released after a meal that enhance insulin secretion and suppress glucagon. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are the two main incretins. In CF, the incretin effect is blunted due to damage to enteroendocrine cells in the gut. This contributes to the reduced first-phase insulin secretion and postprandial hyperglycemia. Some research explores whether GLP-1 receptor agonists could benefit CFRD patients—they may improve postprandial glucose and even promote weight gain in some individuals. However, careful monitoring is needed because GLP-1 therapy can delay gastric emptying and cause nausea, which is problematic in underweight CF patients who already struggle with appetite and absorption.

How Hormonal Changes Shape CFRD Management

The complex hormonal interplay means that CFRD cannot be managed by simply applying standard diabetes algorithms. The treatment plan must account for the fluctuating hormonal environment caused by acute illness, pulmonary exacerbations, steroid use, puberty, pregnancy, and even the daily timing of pancreatic enzyme replacement. A successful approach requires a multidisciplinary team—endocrinologists, pulmonologists, dietitians, and nurses—who understand both CF and diabetes.

Tailoring Insulin Therapy to Hormonal Variability

Insulin is the cornerstone of CFRD treatment. Because the primary defect is insulin deficiency, all patients eventually require insulin—oral agents like metformin are generally ineffective and can cause gastrointestinal side effects or lactic acidosis in CF patients with liver impairment. The insulin regimen must be flexible to accommodate high-carbohydrate meals and variable caloric intake. Most CF centers use a basal-bolus regimen with rapid-acting insulin analogs (e.g., lispro, aspart, glulisine) to cover meals and correct hyperglycemia, plus a long-acting basal insulin (e.g., glargine, detemir, degludec). The dose must be adjusted for infections, steroid therapy, and changes in body weight. Continuous glucose monitoring (CGM) has become standard to identify patterns and guide adjustments. For steroid-induced hyperglycemia, adding a scheduled short-acting insulin dose before steroid administration is common. During pulmonary exacerbations, insulin needs increase due to stress hormones and inflammation; after recovery, doses must be reduced to avoid hypoglycemia.

Nutritional Strategies in the Face of Hormonal Challenges

CFRD management is complicated by the high-fat, high-sodium, and high-calorie diet required for CF. Unlike typical diabetes guidelines that restrict simple sugars, CF patients need to consume enough carbohydrates to maintain weight and energy. The goal is to pair insulin dosing with carbohydrate intake using a fixed insulin-to-carbohydrate ratio. Fat and protein also affect postprandial glucose in a delayed manner; some patients benefit from an extended or dual-wave bolus on an insulin pump. The dietitian plays a pivotal role in teaching patients how to count carbohydrates while still achieving the 3,000–4,000 calories per day that many CF adults require. Hormonal fluctuations often alter appetite and absorption—during illness, patients may need more insulin but eat less, increasing hypoglycemia risk.

The Role of CFTR Modulators in Hormonal Restoration

CFTR modulator therapies—such as elexacaftor/tezacaftor/ivacaftor—address the underlying CFTR protein defect. Emerging evidence suggests that these therapies may improve insulin secretion in some patients, potentially reversing or delaying CFRD. By improving pancreatic function, they may reduce the hormonal disruption caused by CF. Modulators can also improve nutritional status and reduce inflammation, which positively affects the entire hormonal milieu. However, not all patients respond equally, and some experience weight gain and increased insulin sensitivity that require adjustments in insulin dosing. Ongoing clinical trials are testing combinations of modulators with targeted diabetes drugs.

Exercise and Muscle Mass as Hormonal Regulators

Exercise improves insulin sensitivity by increasing glucose uptake in muscle independent of insulin. In CF, exercise is also critical for maintaining lung function and clearing mucus. Resistance training to build muscle mass is particularly beneficial because muscle is the primary site of glucose disposal. Hormonal changes during exercise—such as increased catecholamines and growth hormone—can cause transient hyperglycemia, but the long-term effect is improved metabolic control. Patients with CFRD should be counseled on how to adjust insulin for exercise to prevent hypoglycemia, especially during prolonged aerobic activity. Building muscle mass also enhances the anabolic effects of insulin, helping to combat cachexia.

Emerging Therapeutic Approaches Beyond Insulin

While insulin remains the mainstay, research is exploring therapies that target hormonal dysregulation directly. GLP-1 receptor agonists (e.g., liraglutide, semaglutide) have shown promise in small studies for improving postprandial glucose and promoting weight gain in some CF patients, though they carry risks of nausea and delayed gastric emptying. Metformin is generally avoided. Thiazolidinediones are not recommended due to potential fluid retention and bone loss. Inhaled insulin is being investigated as a way to deliver insulin directly to the lungs, potentially reducing systemic side effects. The most exciting development is the use of closed-loop insulin delivery systems—artificial pancreas—designed specifically for CF patients. These systems can adjust insulin delivery based on CGM readings and predict the hormonal storm of an exacerbation. For patients with advanced CF who undergo lung transplantation, post-transplant immunosuppression dramatically alters the hormonal landscape, requiring an entirely new approach to diabetes management.

Current Research and Future Directions

Understanding the hormonal basis of CFRD is an active area of investigation. Researchers are mapping the temporal sequence of islet cell loss in CF pancreas autopsies, studying incretin secretion in response to meals with varying macronutrient compositions, and exploring how CFTR modulators affect the endocrine pancreas. One promising line of inquiry involves peptide-based therapies that target multiple hormone systems simultaneously—for example, dual agonists that activate both GLP-1 and GIP receptors. Another area is the development of biomarkers to predict who will develop CFRD, allowing for early intervention. The CFRD Consortium is tracking outcomes across multiple centers, and the Cystic Fibrosis Foundation continues to update clinical care guidelines.

For further reading on the pathophysiology of CFRD, consult the Cystic Fibrosis Foundation clinical care guidelines. A detailed review of hormonal changes in CF is available on PubMed. For patient-oriented resources, the Diabetes UK CFRD page offers practical advice. Ongoing research updates can be found through the CFRDS Consortium. Finally, information on CFTR modulator therapies and their impact on CFRD is available via the Cystic Fibrosis Foundation.

Conclusion

Hormonal changes in cystic fibrosis are far-reaching and directly shape the course of CFRD. From insulin deficiency and glucagon dysregulation to the effects of stress hormones, adipokines, and sex steroids, each factor adds a layer of complexity to an already challenging disease. Effective management requires a nuanced understanding of these hormonal interactions and a willingness to adapt treatment to the patient’s changing clinical state. With the advent of CFTR modulators and the rapid advancement of diabetes technology, the outlook for individuals with cystic fibrosis and CFRD is improving. By continuing to unravel the hormonal networks at play, the medical community can design more personalized therapies that not only control blood sugar but also support overall health, lung function, and quality of life for those living with CF.